USPTO serial 90354513
AGONY
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- CIURPITA, DREW PETER FISHER
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AGONY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Justin Brown
Justin Brown BROWN BROTHERS LAW LLP1827 HARLEY DRIVEANN ARBOR, MI 48103United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for skin care; Medicated bath preparations; Antibacterial soap; Medicated beauty soap; Medicated skin care preparations, namely, creams, lotions, gels, toners, cleaners and peels; Nutritional supplements in the form of capsules, powder, and gummies; Vitamins; Vitamin supplements; Gummy vitamins; Vitamin supplement patches; Vitamins for pets; Vitamin oils for human consumption; Vitamin fortified beverages for medical purposes; Vitamin enriched bread for therapeutic purposes; Vitamin enriched chewing gum for medical purposes; Mineral supplements; Mineral food supplements; Mineral nutritional supplements; Vitamin and mineral supplements; Enzyme food supplements; Health food supplements; Dietary food supplements; Vitamin tablets; Vitamin preparations; Vitamin drops; Liquid vitamin supplements; Prenatal vitamins; Vitamin preparations in the nature of food supplements; Pharmaceutical preparations, namely, antivirals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Analgesic and muscle relaxant pharmaceutical preparations; Antimicrobial preservatives for cosmetics and pharmaceuticals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for the treatment of eye diseases and conditions; Dermatological pharmaceutical products; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparation for skin care; Pharmaceutical preparations, namely, injectable contraceptives; Potassium preparations for pharmaceutical purposes; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, antihelmintics; Pharmaceutical antitussive-cold preparations; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Alcohol for pharmaceutical purposes; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Antibacterial pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Cardiovascular pharmaceuticals; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for treating halitosis; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating asthma; Pharmaceutical products for the treatment of cancer; Dietary and nutritional supplements for endurance sports | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 14, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 14, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 30, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 28, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 28, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 28, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 20, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 18, 2023 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 18, 2023 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 18, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 3, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 1, 2023 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 1, 2023 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 1, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 27, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 25, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 25, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 25, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 5, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 3, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 3, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 3, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 7, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 13, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 13, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 23, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 7, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 4, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 28, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 8, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 5, 2020 | NWAP | NEW APPLICATION ENTERED | — |